ATRA Dividend History & Description — Atara Biotherapeutics Inc
Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease. When considering the Atara Biotherapeutics Inc stock dividend history, we have taken known splits into account, such that the ATRA dividend history is presented on a split-adjusted ("apples to apples") basis. Atara Biotherapeutics Inc dividend history is presented both in graphical/chart form, and as a ATRA dividend history data table along the right-hand column.